Physician Wealth Advisors’s Maravai LifeSciences MRVI Stock Holding History

Physician Wealth Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-261	Closed	-$849	–	2181
2025 Q4	$849	Hold	261	–	–	﹤0.01%	1687
2025 Q3	$750	Buy	+261	New	+$666	﹤0.01%	1709
2025 Q1	–	Sell	-124	Closed	-$676	–	1495
2024 Q4	$676	Buy	+124	New	+$798	﹤0.01%	1050

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Physician Wealth Advisors's MRVI Position: Q1 2026 in Review

Physician Wealth Advisors sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 261 shares — an estimated $849 sold.

Physician Wealth Advisors first reported a position in MRVI in Q4 2024 and held it in 3 quarters. The position peaked at $849 in Q4 2025. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

Physician Wealth Advisors reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
Physician Wealth Advisors sold 261 Maravai LifeSciences shares in Q1 2026, an estimated $849.
Physician Wealth Advisors first reported a position in Maravai LifeSciences in Q4 2024 and held it in 3 quarters.
Physician Wealth Advisors's Maravai LifeSciences position peaked at $849 in Q4 2025.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Physician Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.